Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study

Table 3 Multivariable logistic regression analysis of factors associated with TMP-SMX use, new user design^a (N = 919)

Characteristic at the time of first rituximab treatment	OR	95% CI
Age (years)	0.99	0.98–0.99
Female sex	0.57	0.42–0.77
Commercial/Medicare (vs Medicaid)	1.68	0.93–3.15
Year of index date (2011–2015 vs > 2015)	1.17	0.86–1.59
Rituximab induction (vs maintenance)	1.40	0.98–2.02
Hospital admission without intensive care (vs no hospitalization)^b	2.59	1.78–3.78
≥ 1 intensive care unit admission (vs no hospitalization)^b	2.93	1.91–4.50
Serious infection^b	0.71	0.44–1.14
Co-morbidity^c	0.88	0.64–1.21
Prednisone 1–19 mg/day (vs none)^d	1.77	1.07–2.89
Prednisone ≥ 20 mg/day (vs none)^d	2.27	1.58–3.29
Methotrexate^b	1.32	0.83–2.07

^a6 months of continuous insurance enrollment prior to rituximab
^bIn the 6 months prior to rituximab
^cAt least one International Classification of Diseases diagnostic code in physician billing or hospitalization data for obstructive lung disease (asthma, bronchiectasis, chronic obstructive pulmonary disease), interstitial lung disease, diabetes, chronic kidney disease, or dialysis
^dDispensed in the month prior to rituximab

ISSN: 1478-6362